DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-992/S-021

Duramed Pharmaceuticals, Inc.
A subsidiary of Barr Laboratories, Inc.
Attention: Joseph A. Carrado, M.Sc., R.Ph.
One Bala Plaza, Suite 324
Bala Cynwyd, PA 19004-1401

Dear Mr. Carrado:

Please refer to your new drug application (NDA) dated June 25, 2002, received June 31, 2002, and accepted for filing August 2, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cenestin (synthetic conjugated estrogens A) 0.45 mg tablets.

We acknowledge receipt of your submissions dated May 30, June 11, July 30, August 5 and September 15, 2003, January 8, 16 and 27, February 3, 4 and 5, 2004. Your submission of August 5, 2003 constituted a resubmission to this application.

This supplemental new drug application provides for the use of Cenestin (synthetic conjugated estrogens A) 0.45 mg tablets for the treatment of moderate to severe vasomotor symptoms associated with the menopause.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and patient package insert) and the immediate container and carton labels submitted on February 5, 2004.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-992/S-021." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your postmarketing study commitment in your submission dated January 16, 2004. This commitment is listed below.

1. To conduct a study to determine the lowest effective dose of Cenestin for the relief of moderate to severe vasomotor symptoms

Protocol Submission:	Within 6 months of the date of this letter
Study Start:	Within 6 months of reaching protocol agreement with Division of Reproductive and Urologic Drug Products
Final Report Submission:	Within 6 months of the study completion

Submit the clinical protocol to your IND for this product. Submit the final study report to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of this commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and the number of patients entered into the study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "**Postmarketing Study Protocol**", "**Postmarketing Study Final Report**", or "**Postmarketing Study Correspondence**."

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kassandra Sherrod, R.Ph., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

Daniel Shames, M.D.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Daniel A. Shames

2/5/04 05:45:55 PM